JP2019507758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507758A5 JP2019507758A5 JP2018544853A JP2018544853A JP2019507758A5 JP 2019507758 A5 JP2019507758 A5 JP 2019507758A5 JP 2018544853 A JP2018544853 A JP 2018544853A JP 2018544853 A JP2018544853 A JP 2018544853A JP 2019507758 A5 JP2019507758 A5 JP 2019507758A5
- Authority
- JP
- Japan
- Prior art keywords
- pridopidine
- pharmaceutically acceptable
- use according
- day
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims description 117
- 229950003764 pridopidine Drugs 0.000 claims description 117
- 150000003839 salts Chemical class 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 230000000626 neurodegenerative effect Effects 0.000 claims description 39
- 208000030533 eye disease Diseases 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 14
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 230000006727 cell loss Effects 0.000 claims description 8
- 229940054534 ophthalmic solution Drugs 0.000 claims description 8
- 239000002997 ophthalmic solution Substances 0.000 claims description 8
- 208000022873 Ocular disease Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 201000004569 Blindness Diseases 0.000 claims description 4
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 4
- 230000005779 cell damage Effects 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 4
- 210000000795 conjunctiva Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical group Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 claims description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 2
- 206010061323 Optic neuropathy Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 229960000571 acetazolamide Drugs 0.000 claims description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000003376 axonal effect Effects 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 229940110759 betaxolol ophthalmic solution Drugs 0.000 claims description 2
- 229960002470 bimatoprost Drugs 0.000 claims description 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 2
- 229960000722 brinzolamide Drugs 0.000 claims description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960001222 carteolol Drugs 0.000 claims description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 2
- 208000037887 cell injury Diseases 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 229960003933 dorzolamide Drugs 0.000 claims description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical group CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- 229960000831 levobunolol Drugs 0.000 claims description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 229960004083 methazolamide Drugs 0.000 claims description 2
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 claims description 2
- 229940100655 ophthalmic gel Drugs 0.000 claims description 2
- 208000020911 optic nerve disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 229960004458 tafluprost Drugs 0.000 claims description 2
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 229940089406 travoprost ophthalmic solution Drugs 0.000 claims description 2
- 229960004317 unoprostone Drugs 0.000 claims description 2
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 229960002704 metipranolol Drugs 0.000 claims 1
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 claims 1
- 230000001499 parasympathomimetic effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 49
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- -1 metiplanolol Chemical compound 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299290P | 2016-02-24 | 2016-02-24 | |
| US62/299,290 | 2016-02-24 | ||
| PCT/US2017/019266 WO2017147366A1 (en) | 2016-02-24 | 2017-02-24 | Treatment of neurodegenerative eye disease using pridopidine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507758A JP2019507758A (ja) | 2019-03-22 |
| JP2019507758A5 true JP2019507758A5 (enExample) | 2020-03-26 |
| JP7034488B2 JP7034488B2 (ja) | 2022-03-14 |
Family
ID=59686581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544853A Active JP7034488B2 (ja) | 2016-02-24 | 2017-02-24 | プリドピジンを使用する神経変性眼疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11738012B2 (enExample) |
| EP (1) | EP3419622B1 (enExample) |
| JP (1) | JP7034488B2 (enExample) |
| AU (1) | AU2017223838B2 (enExample) |
| CA (1) | CA3015512C (enExample) |
| DK (1) | DK3419622T3 (enExample) |
| ES (1) | ES2979123T3 (enExample) |
| HU (1) | HUE066769T2 (enExample) |
| PL (1) | PL3419622T3 (enExample) |
| WO (1) | WO2017147366A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| US20220062255A1 (en) * | 2016-02-24 | 2022-03-03 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| EP3678664A1 (en) | 2017-09-08 | 2020-07-15 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| AU2020243692B2 (en) * | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CA3231791A1 (en) * | 2021-10-11 | 2023-04-20 | Michael Hayden | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| IL134241A (en) * | 2000-01-27 | 2006-06-11 | Finetech Pharmaceutical Ltd | Process for the preparation of latanoprost |
| WO2004103263A2 (en) | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| JP5393654B2 (ja) | 2007-04-12 | 2014-01-22 | イヴァックス インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツンク | 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体 |
| WO2008150954A1 (en) | 2007-05-31 | 2008-12-11 | Joseph Weinstock | Treatment of age-related macular degeneration |
| US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| WO2014052935A2 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| WO2016138130A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| KR20200031446A (ko) | 2018-09-14 | 2020-03-24 | 삼성전자주식회사 | 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치 |
-
2017
- 2017-02-24 CA CA3015512A patent/CA3015512C/en active Active
- 2017-02-24 ES ES17757261T patent/ES2979123T3/es active Active
- 2017-02-24 US US16/078,929 patent/US11738012B2/en active Active
- 2017-02-24 PL PL17757261.7T patent/PL3419622T3/pl unknown
- 2017-02-24 JP JP2018544853A patent/JP7034488B2/ja active Active
- 2017-02-24 AU AU2017223838A patent/AU2017223838B2/en active Active
- 2017-02-24 HU HUE17757261A patent/HUE066769T2/hu unknown
- 2017-02-24 EP EP17757261.7A patent/EP3419622B1/en active Active
- 2017-02-24 DK DK17757261.7T patent/DK3419622T3/da active
- 2017-02-24 WO PCT/US2017/019266 patent/WO2017147366A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507758A5 (enExample) | ||
| US10792288B2 (en) | Preservative free brimonidine and timolol solutions | |
| JP2021102626A5 (enExample) | ||
| AU2011274245B2 (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
| KR102685479B1 (ko) | 안과 약물의 정량적 안와주위 적용 | |
| WO2015105144A1 (ja) | ピリジルアミノ酢酸化合物を含む医薬製剤 | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| JPWO2020087021A5 (enExample) | ||
| JP2021501803A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| JP7346305B2 (ja) | ピリジルアミノ酢酸化合物を含有する医薬製剤 | |
| WO2019024433A1 (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| CN115998888A (zh) | 用于治疗青光眼或高眼压症的药物组合物及其用途 | |
| KR20230098630A (ko) | 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물 | |
| JP2003292442A (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
| Kish | Old and new drug classes expanding to include glaucoma treatments | |
| TWI896143B (zh) | 一種有效延緩及治療近視的藥物組合物 | |
| Kaplowitz et al. | ChapterChapter 17: 17Updated Medical Treatment for Glaucoma | |
| Croasdell | Association for Research in Vision and Ophthalmology (ARVO)-2016 Annual Meeting. Seattle, Washington, USA-April 29-May 5, 2016 | |
| AU2024274803A1 (en) | Pharmaceutical composition for effectively delaying and treating myopia | |
| Lee et al. | Medical therapy for glaucoma | |
| HK40004045A (en) | Preservative free brimonidine and timolol solutions | |
| HK1241269B (zh) | 前列腺素类和一氧化氮供体的组合产品 | |
| HK1118211A (en) | Ophthalmologic compositions and use mode thereof | |
| SA06270472B1 (ar) | طريقة لمعالجة النوعين الاولي والثانوي للغلوكوما | |
| KR20150051491A (ko) | 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물 |